ResearchESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors
ResearchDifferent Diseases, Different Escapes: Trastuzumab Deruxtecan Resistance in HER2-Amplified versus HER2-Low Breast Cancer
ResearchAndrogen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer
ResearchQuantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer
ResearchPEACE: Development and Validation of a Brief Five-Item Sleep Quality Scale for Community and Primary Care
ResearchOral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis
ResearchSerum copper, rubidium, selenium, strontium, and zinc and psychophysical health in adults of the Sarno river Basin: PREVES-STOP 2025 community biomonitoring results
ResearchSERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer
ResearchRise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
ResearchReal-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast ca
ResearchRecurrence risk in HR-positive/HER2-negative early breast cancer: real-world US electronic health records study
ResearchNeoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial
ResearchDevelopment and validation of a human-supervised AI-augmented living oncology evidence platform: a breast cancer pilot study
ResearchTreatment Effect Discrepancy Between PFS and OS in Antibody-Drug Conjugate Trials for Metastatic Breast Cancer: A Meta-Epidemiologic Analysis
ResearchReply to: "Creatinine Assay Methods and Carboplatin Dosing Transparency in the neoCARHP Trial"